NCT Number: NCT03640559
Safety and Tolerability of Seroguard Use
The performed study of safety and tolerability of Seroguard, solution (JSC Pharmasyntez, Russia) in patients, undergoing planned laparoscopic cholecystectomy, demonstrated that patients from the both groups had the similar safety profile
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–75 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
About this study
The present study was conducted as multicenter, randomized, double-blind, parallel group clinical study. After successful completion of screening procedures, patient underwent a planned laparoscopy. Randomization of patients into groups was performed on the day of surgery using envelops. The test drug or the placebo were used at the completion stage of surgery. Monitoring of patient on inpatient basis was performed for 6 days after completion of surgery. Discharge of patient from the hospital with no contraindications was possible on Day 7 of the study. In this case the follow-up of patient was performed on outpatient basis. Follow-up was performed for 4 weeks before Day 28 of the study. Study procedures aimed at evaluation of safety and tolerability of using the test drug or the placebo were identical in main and control groups.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Male and female patients.
- Age from 18 to 75 years, inclusive.
- Signed informed consent form.
- One of the following diagnoses as per International classification of diseases -10:
4.1. K80.1 Calculus of gallbladder with other cholecystitis 4.2. K80.2 Calculus of gallbladder without cholecystitis
- Indications for planned laparoscopic cholecystectomy.
Exclusion criteria
- Recall of informed consent by patient.
- Non-compliance with the rules of participating in the study by patient.
- Getting pregnant.
- Required conversion during surgery.
- Required repeated surgery.
- Development of diseases described in non-inclusion criteria, required use of drugs not provided by the protocol in patient.
- Another reasons appeared during the study and interfering conduction of the study as per the protocol.
Treatment and study plan
Placebos
DrugPrimary outcomes
-
Number of Participants With Adverse Events (AEs)
Time frame: 28 days
Evaluation of safety of the study drugs Seroguard and the Placebo will be performed for all the study subjects at Visits 1-11, based on account of parameter:
- Vital signs (body temperature, BP, HR, RR)
- Laboratory investigations:
- Blood chemistry - total protein, glucose, ALT, AST, total bilirubin, alkaline phosphatase, amylase, creatinine
- Complete blood count - RBC, WBC, platelet count, hemoglobin, hematocrit, WBC differential, ESR
- Coagulogram - coagulation time, international normalized ratio (INR), thrombin time, activated partial thromboplastin time (APTT)
- Urinalysis - color, transparency, pH, specific gravity, protein, glucose, WBC, RBC, bacteria, casts, salts
- 12-channel ECG data - heart rate [HR], PR, QRS, QT intervals and calculated QTc interval
- USG data
- Incidence of adverse reactions
- Incidence of serious adverse reactions
Sponsors and collaborators
Lead sponsor
Pharmasyntez
Industry
Collaborators
- Sciencefiles
Registry information
Official study title
Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Study of Safety and Tolerability of Seroguard, Solution (JSC Pharmasyntez, Russia) in Patients Undergoing a Planned Laparoscopic Cholecystectomy
Important dates
- Study start
- 2015
- Primary completion
- 2015
- Study completion
- 2015
- First posted
- Aug 21, 2018
- Registry last updated
- May 3, 2019
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
PMCF Study for COSEAL® in Gynecologic Surgery
NCT05996809
Adhesion, Cicatrix
Chicago, Illinois, United States
View Trial DetailsPMCF Study for ADEPT® in LaparoscopicGynecologic Surgery
NCT05811585
Adhesion, Cicatrix
Austin, Texas, United States
View Trial DetailsEvaluation of the Efficacy and Safety of a Hyaluronic Acid Gel in Adhesion Prevention After Open Thyroidectomy.
NCT05036525
Adhesion, Cicatrix
Kaohsiung City, Taiwan
View Trial DetailsMechanical Ileus in the Era of Minimally Invasive Colorectal Surgery
NCT05999162
Adhesion, Cicatrix
Taipei, Taiwan
View Trial Details